2-(乙基硫代)苯甲酸 | 21101-79-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(乙基硫代)苯甲酸
• 英文名称: 2-ethylsulfanylbenzoic acid
• 英文别名: 2-(ethylthio)benzoic acid
• CAS: 21101-79-1
• 化学式: C₉H₁₀O₂S
• mdl: MFCD00094046
• 分子量: 182.243
• InChiKey: GLGKZKZNXSHACI-UHFFFAOYSA-N

物化性质

• 熔点：
  130-131 °C
• 沸点：
  310.1±25.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  62.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2930909090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(Ethylthio)benzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(Ethylthio)benzoic acid
CAS number: 21101-79-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H10O2S
Molecular weight: 182.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(乙基硫代)苯甲酸 在 三氯氧磷 作用下， 生成 2-ethylsulfanyl benzoic acid chloride
  参考文献：
  名称：

  （2-烷基硫代苯甲酰基）二茂铁的合成，光谱表征和电化学性能。2-甲硫基，2-乙硫基和2-异丙硫基衍生物的晶体结构

  摘要：

  一锅法合成了七种新的（2-烷基硫代苯甲酰基）二茂铁，这是通过将二茂铁与相应的羧酸和三氯化磷原位生成的酰氯进行Friedel-Crafts酰化反应而实现的。所得化合物通过光谱数据（UV，IR，1 H和13NMR），而其电化学性质已通过循环伏安法研究。还报告了其中三个的单晶X射线结构测定。这三种衍生物均表现出分子内C–H…O相互作用，其中涉及环戊二烯基（Cp）环的供体和羰基氧作为受体。这种相互作用有利于两个部分的共面排列。符合C–O键的向量与相应的Cp平面之间的夹角均小于6.4°。常规的氢键在这三个晶体结构中都不存在，但是已经发现并详细分析了某些类型的C–H…O，C–H…S和C–H…π类型的弱分子间相互作用。

  DOI：

  10.1016/j.poly.2010.04.034
• 作为产物：
  描述：

  methyl 2-(ethylthio)benzoate 在 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 2-(乙基硫代)苯甲酸
  参考文献：
  名称：

  基于2-（苄基亚磺酰基）苯甲酸支架的选择性hCAs抑制剂的设计，合成和生物学活性

  摘要：

  抽象的 合成了大量基于2-（苄基亚磺酰基）苯甲酸支架的衍生物库，并作为针对人碳酸酐酶的四种不同同工型的非典型抑制剂进行了测试（hCA I，II，IX和XII，EC 4.2.1.1）。对主要官能团周围的化学空间的探索导致发现了微摩尔/纳摩尔范围内的选择性hCA IX抑制剂，从而在这种多功能支架内建立了稳固的结构-活性关系。进行了一些选定手性化合物的HPLC分离和相应对映异构体的生物学评估，并对活性最高的衍生物进行了分子建模研究。

  DOI：

  10.1080/14756366.2019.1651315

文献信息

• Second-Generation Non-Covalent NAAA Inhibitors are Protective in a Model of Multiple Sclerosis
  作者：Marco Migliore、Silvia Pontis、Angel Luis Fuentes de Arriba、Natalia Realini、Esther Torrente、Andrea Armirotti、Elisa Romeo、Simona Di Martino、Debora Russo、Daniela Pizzirani、Maria Summa、Massimiliano Lanfranco、Giuliana Ottonello、Perrine Busquet、Kwang-Mook Jung、Miguel Garcia-Guzman、Roger Heim、Rita Scarpelli、Daniele Piomelli

  DOI：10.1002/anie.201603746

  日期：2016.9.5

  intracellular cysteine amidase, N‐acylethanolamine acid amidase (NAAA). Even though NAAA may offer a new target for anti‐inflammatory therapy, the lipid‐like structures and reactive warheads of current NAAA inhibitors limit the use of these agents as oral drugs. A series of novel benzothiazole–piperazine derivatives that inhibit NAAA in a potent and selective manner by a non‐covalent mechanism are

  棕榈酰乙醇酰胺（PEA）和油酰乙醇酰胺（OEA）是抑制炎症的内源性脂质介体。它们的作用被细胞内半胱氨酸酰胺酶，N-酰基乙醇胺酸酰胺酶（NAAA）终止。尽管NAAA可能为抗炎治疗提供新的靶标，但目前NAAA抑制剂的类脂质结构和反应弹头限制了将这些试剂用作口服药物。描述了一系列通过非共价机制有效和选择性抑制NAAA的新型苯并噻唑-哌嗪衍生物。此类的原型成员（8）在多发性硬化症（MS）的小鼠模型中显示出较高的口服生物利用度，可进入中枢神经系统（CNS）的功能以及强大的活动。该化合物是第二代非共价NAAA抑制剂的例证，可用于治疗MS和其他慢性CNS疾病。
• [EN] DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1<br/>[FR] UTILISATION DE DIARYLTRIAZOLES COMME INHIBITEURS DE LA 11-BETA-HYDROXYSTEROIDE DESHYDROGENASE-1
  申请人：MERCK & CO INC

  公开号：WO2005097759A1

  公开（公告）日：2005-10-20

  2,5-Diaryl-1,2,4-triazole derivatives of structural formula I are selective inhibitors of the 11β-hydroxysteroid dehydrogenase Type 1 enzyme (11β-HSD-1). The compounds are useful for the treatment of diabetes, hyperglycemia, obesity, insulin resistance, atherosclerosis, dyslipidemia, hyperlipidemia, hypertension, and Metabolic Syndrome. Also disclosed are novel compounds of structural formula II which are inhibitors of 11β-HSD-1.

  2,5-二芳基-1,2,4-三唑衍生物的结构式I是11β-羟基类固醇脱氢酶1型酶（11β-HSD-1）的选择性抑制剂。这些化合物用于治疗糖尿病、高血糖、肥胖、胰岛素抵抗、动脉硬化、血脂异常、高血脂、高血压和代谢综合征。还公开了结构式II的新化合物，它们是11β-HSD-1的抑制剂。
• [EN] AN IMPROVED PROCESS FOR PREPARATION OF AMISULPRIDE<br/>[FR] PROCÉDÉ AMÉLIORÉ DE PRÉPARATION D'AMISULPRIDE
  申请人：LUPIN LTD

  公开号：WO2011158084A1

  公开（公告）日：2011-12-22

  The present invention is related to a novel process for the preparation of amisulpride (I) which involves : methylation of 4-amino-salicylic-acid (VI) with dimethyl sulphate and base, optionally in presence of TBAB to obtain 4-amino-2-methoxy methyl benzoate (VII) and (ii) oxidation of 4-amino-2-methoxy-5-ethyl thio benzoic acid (IX) or 4-amino-2-methoxy-5- ethyl thio methyl benzoate (X) with oxidizing agent in the presence of sodium tungstate or ammonium molybdate to give 2-methoxy-4-amino-5-ethyl-sulfonyl benzoic acid (IV) or 2- methoxy-4-amino-5-ethyl-sulfonyl methyl benzoate (XI) respectively.

  本发明涉及一种制备阿米舒普利（I）的新工艺，包括：用二甲基硫酸酯和碱甲基化4-氨基水杨酸（VI），可选地在TBAB存在下，以获得4-氨基-2-甲氧基甲基苯甲酸酯（VII）和（ii）在钨酸钠或钼酸铵存在下，用氧化剂氧化4-氨基-2-甲氧基-5-乙基硫基苯甲酸（IX）或4-氨基-2-甲氧基-5-乙基硫基甲基苯甲酸酯（X），分别得到2-甲氧基-4-氨基-5-乙基磺酰基苯甲酸（IV）或2-甲氧基-4-氨基-5-乙基磺酰基甲基苯甲酸酯（XI）。
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2013096151A1

  公开（公告）日：2013-06-27

  The invention is directed to substituted quinoline derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R1, R2, R3; R4; and R5 are defined herein. The compounds of the invention are inhibitors of lactate dehydrogenase A and can be useful in the treatment of cancer and diseases associated with tumor cell metabolism, such as cancer, and more specifically cancers of the breast, colon, prostate and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting lactate dehydrogenase A activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及取代喹啉衍生物。具体而言，该发明涉及符合以下式（I）的化合物：其中R1、R2、R3；R4；和R5在此处被定义。该发明的化合物是乳酸脱氢酶A的抑制剂，可用于治疗癌症和与肿瘤细胞代谢相关的疾病，如乳腺癌、结肠癌、前列腺癌和肺癌等。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物来抑制乳酸脱氢酶A活性和治疗相关疾病的方法。
• [EN] BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE BENZOFURANE ET DE BENZOTHIOPHÈNE UTILISÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR PGE2
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：WO2018210987A1

  公开（公告）日：2018-11-22

  The present invention relates to benzofurane and benzothiophene derivatives of formula (I) Formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

  本发明涉及公式(I)的苯并呋喃和苯并噻吩衍生物，其中(R1)n，R2，R3，R4a，R4b，R5a，R5b和Ar1如描述中所述，并且它们在通过调节免疫应答包括在肿瘤中重新激活免疫系统的治疗中的用途。该发明还涉及公式(II)的新型苯并呋喃和苯并噻吩衍生物及其作为药物的用途，其制备，其药学上可接受的盐，以及其作为药物的用途，含有一个或多个公式(I)化合物的药物组合物，特别是它们作为前列腺素2受体EP2和/或EP4的调节剂的用途。